Anthropic appoints Novartis CEO Vas Narasimhan to Board

AI Impact Summary

The appointment of Vas Narasimhan to Anthropic’s Board of Directors signals a strategic move to bolster the company’s governance and align it with its public benefit mission. Narasimhan’s extensive experience in pharmaceutical development and regulatory oversight, particularly within Novartis, brings a critical perspective to Anthropic’s efforts in deploying AI responsibly, especially given the company’s focus on long-term societal impact. This addition strengthens Anthropic’s board with expertise relevant to navigating the complex challenges of scaling impactful AI technology while maintaining a commitment to ethical development and deployment.